Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 13/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.43 |
| ▸ | PLA2G2E | Q9NZK7 | 2/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.43 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.43 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.43 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136 | 0.88 | MTNR1B (0.60) | MTNR1AMTNR1BPSEN1PSEN2APH1B | |
| SCHEMBL5696981 | 0.86 | PLA2G2A (0.49) | MTNR1AMTNR1BPSEN1PSEN2APH1B | |
| SCHEMBL5696902 | 0.86 | PSEN1 (0.43) | MTNR1AMTNR1BPSEN1PSEN2APH1B | |
| SCHEMBL5697202 | 0.82 | PLA2G2A (0.43) | MTNR1AMTNR1BPSEN1PSEN2APH1B | |
| SCHEMBL4757197 | 0.80 | MTNR1B (0.52) | MTNR1AMTNR1BPLA2G2APLA2G1BCCR2 | |
| SCHEMBL14620974 | 0.77 | MTNR1B (0.52) | MTNR1AMTNR1BPLA2G2APLA2G1BPLA2G10 | |
| SCHEMBL13632216 | 0.77 | MTNR1A (0.54) | MTNR1AMTNR1BPLA2G2APLA2G1BPLA2G10 | |
| SCHEMBL26473 | 0.77 | MTNR1B (0.67) | MTNR1AMTNR1BPLA2G2ACCR2 | |
| SCHEMBL3197253 | 0.76 | MAPK1 (0.50) | MTNR1AMTNR1BPSEN1PSEN2APH1B | |
| SCHEMBL26613 | 0.75 | PLA2G2A (0.59) | MTNR1AMTNR1BPLA2G2APLA2G1BPLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100492-B1 | INDOLE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| US-6610728-B2 | SPLA2 inhibitor, secretory phospholiase A2 inhibitors 1H-indole-3-glyoxylamide compound or a pharmaceutically acceptable salt, solvate, or a prodrug | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-6576654-B1 | Administering a 1H-indole-3-glyoxylamide derivative as secretary phopholipase A2 inhibitor | ELI LILLY AND COMPANY | 2003-06-10 | — | — | US | disclosed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | disclosed |
| US-6451839-B1 | Indole sPLA2 inhibitors | ELI LILLY AND COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6436983-B1 | ADMINISTERING ((3-(2-AMINO-1,2-DIOXOETHYL)2-ETHYL-1 (PHENYLMETHYL)INDOL-4YL)OXY)ACETIC ACID, AS A NON-PANCREATIC SECRETORY PHOSPHOLIPASE SUPPRESSORS; PROPHYLAXIS OF NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2002-08-20 | — | — | US | disclosed |
| EP-1039901-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999025339-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | MTNR1A 1292/4885MTNR1B 1484/4885PSEN1 3110/4885 |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | MTNR1A 136/4885MTNR1B 191/4885PSEN1 2281/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | MTNR1A 519/4885MTNR1B 549/4885PSEN1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.